Description
Book SynopsisIntroduction to volume: Biomarkers in Psychiatry.- Part I: Government and Pharma perspectives on biomarker development.- Biomarker Methodologies: a NIMH Perspective.- Neural Circuitry-related biomarkers for drug development in psychiatry An industry perspective.- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective.- Part II: Biomarker methodologies and Translational Approaches.- Methods for and use of functional magnetic resonance imaging in psychiatry.- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches.- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications.- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry.- Rodent models for ASD biomarker development.- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates.- Part III: Biomarkers in schizophrenia and clinical high risk.- Functional Connectivity Biomarkers in Schizophrenia.- The use of event-related potentials in the study of schizophrenia: An overview.- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here?.- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia.- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience.- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia.- Part IV: Biomarkers in ASD.- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG).- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder.- Delineating a pathway for the discovery of functional connectome biomarkers of autism.- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process.- Part V: Other disorders.- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD.- Neuroimaging Biomarkers in Parkinson's Disease.- Biomarkers of Auditory-Verbal Hallucinations.- Part VI: Cross-diagnostic methodologies.- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes.- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence.- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders.- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.
